Chien‐Hsiang Weng - research works

These associations remained robust across all sensitivity analyses and were consistently observed across major patient subgroups.

This association remained consistent across multiple sensitivity analyses, including the exclusion of individuals with early POAG events after the index date, restricting the cohort to patients with ≥1 subsequent prescription during follow-up, an intention-to-treat design, and limiting the analysis exclusively to individuals with an ophthalmology visit.

The cohort included 36 927 tadalafil users and 36 927 matched non-PDE5i users.

Elevated risks were observed for ocular hypertension (HR 1.32; 95% CI 1.06 to 1.65), primary open-angle glaucoma (HR 1.33; 95% CI 1.05 to 1.67) and initiation of glaucoma treatment (HR 1.33; 95% CI 1.20 to 1.47).

No significant associations were found for low-tension or primary angle-closure glaucoma.

Tadalafil users had a higher 5-year cumulative incidence than non-users (3.93% vs 3.16%; p<0.001), with consistent risk in men >50 years, white population and across comorbidities, remaining robust to 1-, 3- and 6-month lag times.